INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Elevance

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Elevance Health, Inc. due to alleged violations of federal securities laws, encouraging affected investors to come forward [2][4]. Group 1: Legal Investigation - The law firm is looking into claims against Elevance Health, reminding investors of the July 11, 2025 deadline to seek the role of lead plaintiff in a federal securities class action [2]. - The complaint alleges that Elevance and its executives made false or misleading statements regarding the monitoring of cost trends and the adequacy of premium rates for Medicaid programs [4]. Group 2: Financial Disclosures - On July 17, 2024, Elevance disclosed an expectation of increased utilization in Medicaid, leading to a stock price decline of $32.21 per share, or 5.8$1.33, or 13.7%, and lowered its EPS guidance for 2024 from $37.20 to$33.00, or 11.3%, causing a further stock price decline of $52.61 per share, or 10.6% [6]. Group 3: Investor Participation - The lead plaintiff in the class action will be the investor with the largest financial interest who is typical of class members, and any member can move to serve as lead plaintiff or remain an absent class member [7]. - The firm encourages anyone with information regarding Elevance's conduct to contact them, including whistleblowers and former employees [8].